Parkwood LLC’s Phathom Pharmaceuticals PHAT Stock Holding History

Parkwood LLC’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-12,918	Closed	-$429K	–	132
2020 Q4	$429K	Buy	+12,918	New	+$523K	0.05%	105

Other funds holding PHAT

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Parkwood LLC's PHAT Position: Q1 2021 in Review

Parkwood LLC sold out of Phathom Pharmaceuticals (PHAT) in Q1 2021, closing a stake of 12,918 shares — an estimated $429K sold.

Parkwood LLC first reported a position in PHAT in Q4 2020 and held it in 1 quarter. The position peaked at $429K in Q4 2020. 84 funds tracked by Wall St. Rank hold PHAT as of Q1 2021.

Parkwood LLC reported no remaining Phathom Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Parkwood LLC sold 12,918 Phathom Pharmaceuticals shares in Q1 2021, an estimated $429K.
Parkwood LLC first reported a position in Phathom Pharmaceuticals in Q4 2020 and held it in 1 quarter.
Parkwood LLC's Phathom Pharmaceuticals position peaked at $429K in Q4 2020.
84 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2021.

Based on Parkwood LLC's 13F filing for Q1 2021, filed 14 May 2021.